Journal
NANOSCALE
Volume 3, Issue 3, Pages 919-924Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c0nr00781a
Keywords
-
Categories
Funding
- Commonwealth of
- National Science Foundation/Department of Energy [CHE-0535644]
- U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC0-206CH11357]
- Australian Research Council
Ask authors/readers for more resources
We demonstrate that oral delivery of self-assembled nanostructured nanoparticles consisting of 5-fluorouracil (5-FU) lipid prodrugs results in a highly effective, target-activated, chemotherapeutic agent, and offers significantly enhanced efficacy over a commercially available alternative that does not self-assemble. The lipid prodrug nanoparticles have been found to significantly slow the growth of a highly aggressive mouse 4T1 breast tumour, and essentially halt the growth of a human MDA-MB-231 breast tumour in mouse xenografts. Systemic toxicity is avoided as prodrug activation requires a three-step, enzymatic conversion to 5-FU, with the third step occurring preferentially at the tumour site. Additionally, differences in the lipid prodrug chemical structure and internal nanostructure of the nanoparticle dictate the enzymatic conversion rate and can be used to control sustained release profiles. Thus, we have developed novel oral nanomedicines that combine sustained release properties with target-selective activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available